No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
CMPX Compass Therapeutics
- 0.955
- -0.075-7.29%
Close Jul 24 16:00 ET
- 1.010
- +0.055+5.77%
Post 19:37 ET
131.38MMarket Cap-2728P/E (TTM)
1.040High0.923Low242.39KVolume1.020Open1.030Pre Close232.32KTurnover0.25%Turnover RatioLossP/E (Static)137.59MShares3.01052wk High0.84P/B93.64MFloat Cap0.76552wk Low--Dividend TTM98.07MShs Float8.800Historical High--Div YieldTTM11.35%Amplitude0.765Historical Low0.958Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Here's Why We're Not Too Worried About Compass Therapeutics' (NASDAQ:CMPX) Cash Burn Situation
Compass Therapeutics, Inc.'s (NASDAQ:CMPX) Recent 32% Pullback Adds to One-year Year Losses, Institutional Owners May Take Drastic Measures
12 Health Care Stocks Moving In Monday's After-Market Session
H.C. Wainwright Maintains Compass Therapeutics(CMPX.US) With Buy Rating, Maintains Target Price $10
Compass Therapeutics to Participate in the Jefferies Global Healthcare Conference
Compass Therapeutics: Bisker-Leib Will Continue to Be Available as Senior Consultant for Next 15 Mos >CMPX
Comments
$Compass Therapeutics(CMPX.US$
NEWS
Compass Therapeutics Announces First Patient Dosed in the Phase 1 Study of CTX-8371 in Patients with Solid Tumors
Compass Therapeutics dosed the first patient in the Phase 1 trial of CTX-8371, a novel dual checkpoint blocker targeting PD-1 and PD-L1 in patients with solid tumors. The study aims to evaluate the drug's efficacy in patients who failed prior checkpoint blocker treatments.
NEWS
Compass Therapeutics Announces First Patient Dosed in the Phase 1 Study of CTX-8371 in Patients with Solid Tumors
Compass Therapeutics dosed the first patient in the Phase 1 trial of CTX-8371, a novel dual checkpoint blocker targeting PD-1 and PD-L1 in patients with solid tumors. The study aims to evaluate the drug's efficacy in patients who failed prior checkpoint blocker treatments.
1
Gainers:
• $Livent(LTHM.US$ +22.58% (it posted better-than-expected quarterly earnings and raised its 2022 revenue forecast)
• $Super Micro Computer(SMCI.US$ +11.01% (earnings reports)
• $Oatly Group AB(OTLY.US$ +8.31% (earnings reports)
• $BlueLinx Holdings(BXC.US$ +9.7% (increases share repurchase authorization to $100 mln; enters into $60 mln accelerated repurchase agreement)
• $Starbucks(SBUX.US$ +7.18% (matched estimates wi...
• $Livent(LTHM.US$ +22.58% (it posted better-than-expected quarterly earnings and raised its 2022 revenue forecast)
• $Super Micro Computer(SMCI.US$ +11.01% (earnings reports)
• $Oatly Group AB(OTLY.US$ +8.31% (earnings reports)
• $BlueLinx Holdings(BXC.US$ +9.7% (increases share repurchase authorization to $100 mln; enters into $60 mln accelerated repurchase agreement)
• $Starbucks(SBUX.US$ +7.18% (matched estimates wi...
26
1
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg